Lawyers touting a $500 million settlement over insulin pricing are back at the drawing board after a judge refused to certify their class.
Insulin prices have drawn the interest of federal and state regulators, many of which, including California, have sued manufacturers Eli Lilly, Novo Nordisk and Sanofi-Aventis and, in some cases, numerous pharmacy benefit managers.
Meanwhile, a consumer class action humming along for six years in U.S. District Court in the District of New Jersey reached the first substantive settlement, in which Eli Lilly agreed to cap the price of insulin at $35 per month for four years and provide a $13.5 million cash fund for certain consumers.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Amanda Bronstad
Amanda Bronstad is the ALM staff reporter covering class actions and mass torts nationwide. She writes the email dispatch Law.com Class Actions: Critical Mass. She is based in Los Angeles.
